Although the clinical role of KIT inhibitors in treatment of AML has not been established, there are a few clinical reports suggesting an anti-leukemic effect of KIT inhibitor (e.g., dasatinib) for KIT-mutated AML [106,107]. This evidence concerns the gene KIT and acute myeloid leukemia.